164 related articles for article (PubMed ID: 23524567)
1. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: a case control study.
Zhu Q; Liu T
Mol Biol Rep; 2012 Sep; 39(9):8679-85. PubMed ID: 22696188
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.
Gao L; Feng Z; Li Q; Li L; Chen L; Xiao T
Tumour Biol; 2014 Apr; 35(4):2997-3002. PubMed ID: 24248544
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 4 polymorphisms and the prognosis of non-Hodgkin lymphoma.
Cha Z; Zang Y; Guo H; Gu H; Tu X; Song H; Qian B
Mol Biol Rep; 2014 Feb; 41(2):1165-70. PubMed ID: 24381107
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
[TBL] [Abstract][Full Text] [Related]
6. RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC.
Wang X; Cui E; Zeng H; Hua F; Wang B; Mao W; Feng X
PLoS One; 2012; 7(10):e43734. PubMed ID: 23071492
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC.
Wu F; Hu N; Li Y; Bian B; Xu G; Zheng Y
Cell Oncol (Dordr); 2012 Jun; 35(3):175-80. PubMed ID: 22476961
[TBL] [Abstract][Full Text] [Related]
9. The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients.
Tian G; Wang M; Xu X
Cell Biochem Biophys; 2014 Jul; 69(3):475-9. PubMed ID: 24464627
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
[TBL] [Abstract][Full Text] [Related]
11. The role of fibroblast growth factor receptor 4 polymorphisms in the susceptibility and clinical features of ischemic stroke.
Yin C; Li S; Zhao W; Guo Y; Zhang Y; Feng J
J Clin Neurosci; 2014 Feb; 21(2):246-9. PubMed ID: 24239227
[TBL] [Abstract][Full Text] [Related]
12. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
[TBL] [Abstract][Full Text] [Related]
14. Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.
Wu F; Zhang J; Hu N; Wang H; Xu T; Liu Y; Zheng Y
Cancer Epidemiol; 2014 Dec; 38(6):728-32. PubMed ID: 25246379
[TBL] [Abstract][Full Text] [Related]
15. RECK gene polymorphisms influence NSCLC susceptibility, but not the chemotherapy response status in Chinese cohort.
Chen X; Jiang F; Shi N; Zhou H; Zhang L; Chen Y; Zheng Y; Yan TG
Cell Biochem Biophys; 2014 Jul; 69(3):567-71. PubMed ID: 24510537
[TBL] [Abstract][Full Text] [Related]
16. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
17. [Relationship of insulin-like growth factor receptor single nucleotide polymorphism (SNP) with platinum-based chemotherapy outcomes in advanced non-small cell lung cancer].
Chen Y; Shao H; Li H; Han L; Zhang X
Zhongguo Fei Ai Za Zhi; 2012 Feb; 15(2):65-71. PubMed ID: 22336232
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.
Li W; Yue W; Zhang L; Zhao X; Ma L; Yang X; Zhang C; Wang Y; Gu M
Lung; 2012 Feb; 190(1):91-8. PubMed ID: 22109568
[TBL] [Abstract][Full Text] [Related]
19. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.
Zhu X; Lin MCM; Fan W; Tian L; Wang J; Ng SS; Wang M; Kung H; Li D
Chest; 2012 Jun; 141(6):1466-1472. PubMed ID: 21940774
[TBL] [Abstract][Full Text] [Related]
20. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
Liu HF; Liu JS; Deng JH; Wu RR
Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
